Siemens to acquire Corindus Vascular Robotics for $1.1B in cash

Corindus
The merger aims to couple Siemens’ tools in digital imaging and artificial intelligence with Corindus' CorPath precision robotics platform for cardiovascular disease. (Image: Corindus)

Siemens Healthineers is dashing deeper into surgical robotics, shelling out $1.1 billion in cash to pick up Corindus Vascular Robotics, maker of a minimally invasive platform for coronary, peripheral and neurovascular procedures. 

Siemens’ medical solutions subsidiary will acquire all issued and outstanding shares of Corindus’ common stock for $4.28 per share. 

The merger—expected to close by the end of the year, subject to approval by Corindus’ shareholders—aims to couple Siemens’ established surgery tools in digital imaging and artificial intelligence with a precision robotics platform for cardiovascular disease.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“The tremendous technology synergies and shared vision between both companies should allow us to achieve a seamless integration between our businesses,” Corindus President and CEO Mark Toland said in a statement. “We believe the transaction will deliver immediate, compelling and certain value to all Corindus stockholders, as well as substantial benefits to our customers.”

Based in Waltham, Massachusetts, Corindus received FDA clearance in March 2018 for new automated surgery software for its CorPath platform, designed to speed up the placement of catheters and guidewires during more complex percutaneous coronary intervention procedures.

RELATED: Special Report—The top 10 medtech companies of 2024 | Siemens Healthineers 

One of Corindus' consumable surgery
cassettes. (Image: Corindus)

“The acquisition of Corindus, combined with Siemens’ strong advanced therapies portfolio will help further advance the growth of vascular robotics,” said Siemens’ advanced therapies president, Michel Therin. “The integration of our technologies could lead to reduced variability, improved efficiency, expanded access to care and ultimately improved patient outcomes.”

The two companies unveiled the news alongside Corindus’ second-quarter earnings report, with its $4.6 million in revenue comprising a 175% increase compared to the $1.7 million raised in the same quarter the year before. That included the sales of six new CorPath GRX systems, as well as one upgrade and two units sold to distributors in Italy and Japan. It also sold 700 of its single-use robotic cassettes used in the procedures, for about $300,000.

In addition, Corindus recently received regulatory approval for a new indication expanding its platform’s use in neurovascular interventions in Australia and New Zealand. Currently, the company counts an installed base of at least 68 systems.

Suggested Articles

The FDA has cleared Drawbridge Health’s blood collection device designed to help monitor long-term blood sugar levels in people with diabetes.

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

FierceMedTech Fierce 15 winner 10x Genomics announced its plans for a $100 million IPO, on the Nasdaq using the symbol TXG.